Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646

Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study

Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959

Diastolic Heart Failure — Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle

Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,577

New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I

Zile, M. R., & Brutsaert, D. L. (2002) · Circulation · doi:10.1161/hc1102.105289 · Cited by 1,185

Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function

Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,139

Cardiac Fibroblast

Souders, C. A., Bowers, S., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 1,018

Matrix Metalloproteinases

Spinale, F. G. (2002) · Circulation Research · doi:10.1161/01.res.0000013290.12884.a3 · Cited by 735

Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension

van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J. J., Schalkwijk, C. G., Bronzwaer, J. G. F., Diamant, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.728550 · Cited by 723

Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction

Borlaug, B. A., Melenovsky, V., Russell, S. D., Kessler, K., Pacak, K., Becker, L. C., & Kass, D. A. (2006) · Circulation · doi:10.1161/circulationaha.106.632745 · Cited by 699

Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine

Polsinelli, V. B., & Shah, S. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1288717 · Cited by 23

Myocardial inflammatory cells in cardiac amyloidosis

Simon, P., Behrens, H., Kristen, A. V., & Röcken, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-74289-5 · Cited by 22

The Cardiohepatic Axis in Metabolic Disease

Hakeem, A. N., van Berlo, J. H., & Revelo, X. S. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.05.004 · Cited by 24

The alarmin tandem: unraveling the complex effect of S100A8/A9 – from atherosclerosis to cardiac arrhythmias

Cozac, D. A., Halațiu, V.-B., & Scridon, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630410 · Cited by 22

Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches

Toth, P. P., & Gauthier, D. F. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1842620 · Cited by 22

The influence of epigenetics and inflammation on cardiometabolic risks

Raghubeer, S. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.02.006 · Cited by 23

Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension.

Szelényi, Z., Fazakas, Á., Szénási, G., Kiss, M., Tegze, N., Fekete, B. C., Nagy, E., Bodó, I., Nagy, B., Molvarec, A., et al. (2015) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2015.01.001 · Cited by 22

Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis

Becher, P. M., Gotzhein, F., Klingel, K., Escher, F., Blankenberg, S., Westermann, D., & Lindner, D. (2017) · Journal of Immunology Research · doi:10.1155/2017/6590609 · Cited by 22

Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction

Zhang, Z., Nkuipou‐Kenfack, E., Yang, W., Wei, F., Cauwenberghs, N., Thijs, L., Huang, Q., Feng, Y., Schanstra, J. P., Kuznetsova, T., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.03.007 · Cited by 22

Heart failure with preserved ejection fraction: the missing pieces in diagnostic imaging

Loai, S., & Cheng, H. M. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09836-8 · Cited by 22

Heart Failure With a Preserved Ejection Fraction

Maurer, M. S., & Hummel, S. L. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.054 · Cited by 22

Opportunities and challenges for the use of human samples in translational cardiovascular research: a scientific statement of the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Cardiovascular Surgery, the ESC Council on Basic Cardiovascular Science, the ESC Scientists of Tomorrow, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the Heart Failure Association of the ESC

Davidson, S. M., Andreadou, I., Antoniades, C. A., Bartúnek, J., Basso, C., Brundel, B. J. J. M., Byrne, R. A., Chiva‐Blanch, G., Martins, P. A. D. C., Evans, P. C., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf023 · Cited by 21

Current applications of biomarkers in cardiomyopathies

COATS, C. J., Heywood, W., Mills, K. A., & Elliot, P. M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1053873 · Cited by 21

Cytokine-Mediated Alterations of Human Cardiac Fibroblast’s Secretome

Bräuninger, H., Thottakara, T., Schön, J., Voss, S., Dhople, V. M., Warnke, S., Scherschel, K., Schrage, B., Kirchhof, P. F., Blankenberg, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212262 · Cited by 21

Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review

Garg, A., Virmani, D., Agrawal, S., Agarwal, C., Sharma, A., Stefanini, G. G., & Kostis, J. B. (2016) · Cardiology · doi:10.1159/000450573 · Cited by 21

Pathogenic roles of neutrophil‐derived alarmins (S100A8/A9) in heart failure: From molecular mechanisms to therapeutic insights

Bai, B., Xu, Y., & Chen, H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15998 · Cited by 20

Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases

Mangione, M. C., Wen, J., & Cao, D. J. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.10.011 · Cited by 20

Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications

Vecchia, G. L., Fumarulo, I., Caffè, A., Chiatto, M., Montone, R. A., & Aspromonte, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147628 · Cited by 20

Serum Levels of the Soluble Il-1 Receptor Family Member St2 And Right Ventricular Dysfunction

Agoşton-Coldea, L., Lupu, S., Hicea, S., Paradis, A., & Mocan, T. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.116 · Cited by 20

Cardiomyocyte Ca2+dynamics: clinical perspectives

Aronsen, J. M., Louch, W. E., & Sjaastad, I. (2016) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2015.1136079 · Cited by 20

Physical activity and exercise training in heart failure with preserved ejection fraction: gathering evidence from clinical and pre-clinical studies

Schmidt, C., Moreira‐Gonçalves, D., Santos, M., Leite-Moreira, A. F., & de Oliveira, J. J. F. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09973-5 · Cited by 20

FFAR4 regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome

Zhang, N., Harsch, B. A., Zhang, M. J., Gyberg, D. J., Stevens, J. A., Wagner, B. M., Mendelson, J. B., Patterson, M. T., Orchard, D. A., Healy, C. L., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100374 · Cited by 19

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling

Stencel, J. D., Alai, H. R., Dhore-Patil, A., Urina‐Jassir, D., & Jemtel, T. H. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093341 · Cited by 20

Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction

Habel, N., Infeld, M. M., Bernknopf, J., Meyer, M., & Lustgarten, D. L. (2023) · Heart Rhythm O2 · doi:10.1016/j.hroo.2023.12.001 · Cited by 19

Beyond Encapsulation: Exploring Macrophage-Fibroblast Cross Talk in Implant-Induced Fibrosis

Sudarsanam, P. K., Alsema, E. C., Beijer, N. R. M., van Kooten, T. G., & de Boer, J. (2024) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2023.0300 · Cited by 18

Coronary Microvascular Dysfunction: Insights on Prognosis and Future Perspectives

Gurgoglione, F. L., Benatti, G., Denegri, A., Donelli, D., Covani, M., Gregorio, M. D., Dallaglio, G., Navacchi, R., & Niccoli, G. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25757 · Cited by 18

Activated fibroblasts in cardiac and cancer fibrosis: An overview of analogies and new potential therapeutic options

Nicolini, G., Balzan, S., & Forini, F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121575 · Cited by 18

Multi-omic analysis of the cardiac cellulome defines a vascular contribution to cardiac diastolic dysfunction in obese female mice

Dona, M. S. I., Hsu, I., Meuth, A. I., Brown, S. M., Bailey, C. A., Aragonez, C. G., Russell, J. J., Krstevski, C., Aroor, A. R., Chandrasekar, B., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-00983-6 · Cited by 18

The cytokine trio - visfatin, placental growth factor and fractalkine – and their role in myocardial infarction with non-obstructive coronary arteries (MINOCA)

Stangret, A., Dykacz, W., Jabłoński, K., Wesolowska, A. M., Klimczak‐Tomaniak, D., Kochman, J., & Tomaniak, M. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.08.009 · Cited by 18

HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients

Zhou, R., Xia, Y., Li, Z., Wu, L., Shi, Y. P., Ling, Z., & Zhang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-55996-5 · Cited by 18

Periodontitis and myocardial hypertrophy

Suzuki, J.-I., Sato, H., Kaneko, M., Yoshida, A., Aoyama, N., Akimoto, S., Wakayama, K., Kumagai, H., Ikeda, Y., Akazawa, H., et al. (2016) · Hypertension Research · doi:10.1038/hr.2016.146 · Cited by 18

Targeted HFpEF therapy based on matchmaking of human and animal models

Aizpurua, A. B., Schroen, B. L. M., van Bilsen, M., & van Empel, V. P. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2018 · Cited by 20

Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models

Brenes-Castro, D. A., Castillo, E. C., Vázquez‐Garza, E., Torre‐Amione, G., & García‐Rivas, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123719 · Cited by 19

Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype

Li, Y., Kubo, H., Yu, D., Yang, Y., Johnson, J. P., Eaton, D., Berretta, R. M., Foster, M., McKinsey, T. A., Yu, J., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00594.2022 · Cited by 18

MicroRNAs in Peripheral Mononuclear Cells as Potential Biomarkers in Hypertensive Patients With Heart Failure With Preserved Ejection Fraction

Marketou, M. E., Kontaraki, J. E., Maragkoudakis, S., Patrianakos, A. P., Konstantinou, J., Nakou, H., Vougia, D., Logakis, J., CHLOUVERAKIS, G. I., Vardas, P. E., et al. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy035 · Cited by 18

Early cardiac dysfunction in children and young adults with perinatally acquired HIV

McCrary, A. W., Nyandiko, W. M., Ellis, A. M., Chakraborty, H., Muehlbauer, M. J., Koech, M. M., Daud, I. I., Birgen, E., Thielman, N. M., KISSLO, J. A., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002445 · Cited by 17

Epigenetics in Heart Failure: Role of DNA Methylation in Potential Pathways Leading to Heart Failure with Preserved Ejection Fraction

Rabkin, S. W., & Wong, C. N. (2023) · Biomedicines · doi:10.3390/biomedicines11102815 · Cited by 17

Update on Heart Failure with Preserved Ejection Fraction

Hummel, S. L., & Kitzman, D. W. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0350-9 · Cited by 17

Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?

Li, J., Becher, P. M., Blankenberg, S., & Westermann, D. (2013) · Cardiology Research and Practice · doi:10.1155/2013/130724 · Cited by 17

Heart Failure with Preserved Ejection Fraction

Rose‐Jones, L. J., Rommel, J. J., & Chang, P. P. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.006 · Cited by 17

Extracellular Matrix and Regenerative Therapies from the Cardiac Perspective

Doğan, A., Parmaksız, M., Elçin, A. E., & Elçin, Y. M. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9641-5 · Cited by 17

Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease

Priksz, D., Bombicz, M., Varga, B., Kurucz, A., Gesztelyi, R., Balla, J., Tóth, A., Papp, Z., Szilvássy, Z., & Juhász, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102882 · Cited by 17

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

Udelson, J. E., Lewis, G. D., Shah, S. J., Zile, M. R., Redfield, M. M., Burnett, J. C. J., Mittleman, R. S., Profy, A. T., Seferović, J. P., Reasner, D. S., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.009 · Cited by 17

Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review

Hung, M., Yeh, C., Kounis, N. G., Koniari, I. C., Hu, P., & Hung, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087530 · Cited by 17

A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: Roles of extracellular signal-regulated kinase 1/2 and nuclear factor-κB

He, Y., Zhang, H., Zhang, G., Hou, N., Xiao, Q., Huang, Y., Wu, J., Luo, M.-S., Zhang, G., Quan, Y., et al. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05581.x · Cited by 17

The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction

Hammer, A., Sulzgruber, P., Koller, L., Kazem, N., Hofer, F., Richter, B., Blum, S., Hülsmann, M., Wojta, J., & Niessner, A. (2020) · Mediators of Inflammation · doi:10.1155/2020/6079713 · Cited by 16

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction

Ovchinnikov, A. G., Filatova, A. Y., Potekhina, A. V., Arefieva, T. I., Gvozdeva, A. D., Ageev, F. T., & Belyavskiy, E. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070310 · Cited by 16

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction

Jalink, E. A., Schonk, A. W., Boon, R. A., & Juni, R. P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1300375 · Cited by 16

Prevalence, Incidence, and Outcomes of Diastolic Dysfunction in Isolated Tricuspid Regurgitation

Naser, J. A., Harada, T., Tada, A., Doi, S., Tsaban, G., Pislaru, S. V., Nkomo, V. T., Scott, C. G., Kennedy, A. M., Eleid, M. F., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.05.019 · Cited by 16

Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice

Ellenbroek, G. H. J. M., de Haan, J. J., van Klarenbosch, B. R., Brans, M. A. D., van de Weg, S. M., Smeets, M. B., de Jong, S., Arslan, F., Timmers, L., Goumans, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13678-5 · Cited by 16

Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Shear, F. E. (2019) · Europe PMC (PubMed Central) · Cited by 16

Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation

Correale, M., Leopizzi, A., Mallardi, A., Ranieri, A., Suriano, M. P., D’Alessandro, D., Tricarico, L., Mazzeo, P., Tucci, S., Pastore, G., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.046 · Cited by 16

Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions

Howell, E. H., & Cameron, S. J. (2016) · Cardiology Journal · doi:10.5603/cj.a2016.0063 · Cited by 16

Coronary Microcirculatory Dysfunction in Human Cardiomyopathies

Selthofer-Relatić, K., Mihalj, M., Kibel, A., Stupin, A., Stupin, M., Jukić, I., Koller, Á., & Drenjančević, I. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000140 · Cited by 16

Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges

Saksena, S. V., Slee, A. E., Nagarakanti, R., & Prakash, A. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16625 · Cited by 15

NLRP3 Inflammasome: A New Target for the Treatment of CVD and Depression Comorbidity

Chen, C., Zhang, S., Sheng, M., & Shao, W. (2025) · Mediators of Inflammation · doi:10.1155/mi/4330574 · Cited by 16

Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review

Mancusi, C., Basile, C., Spaccarotella, C., Gargiulo, G., Fucile, I., Paolillo, S., Gargiulo, P., Santoro, C., Manzi, L., Marzano, F., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00629-1 · Cited by 15

Role of Trimethylamine N-Oxide in Heart Failure

Jing, L., Zhang, H., Xiang, Q., Hu, H., Zhai, C., Xu, S., & Tian, H. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507240 · Cited by 16

Heart failure with preserved ejection fraction: The role of inflammation

Liu, H., Magaye, R., Kaye, D. M., & Wang, B. H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176858 · Cited by 17

Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease

Teramachi, R., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Yokoyama, T., Furukawa, T., Yagi, M., Sakamoto, K., Hashimoto, N., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2020.12.010 · Cited by 15

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

Samson, R., & Jemtel, T. H. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021120 · Cited by 16

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo‐DHF trial

Dumeny, L., Vardeny, O., Edelmann, F., Pieske, B. M., Duarte, J. D., & Cavallari, L. H. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2626 · Cited by 15

Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis

Zuern, C. S., Walker, B., Sauter, M., Schaub, M., Chatterjee, M., Mueller, K. A. L., Rath, D., Vogel, S., Tegtmeyer, R., Seizer, P., et al. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0871-y · Cited by 15

Phenotypic and Functional Heterogeneity of Monocyte Subsets in Chronic Heart Failure Patients

Mongirdienė, A., & Liobikas, J. (2022) · Biology · doi:10.3390/biology11020195 · Cited by 15

Heart Failure with Preserved Ejection Fraction

Hummel, S. L. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5198-2_16 · Cited by 15

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF

Zhou, S., Zhou, X., Zhang, P., Zhang, W., Huang, J., Jia, X., He, X., Sun, X., & Su, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1537576 · Cited by 15

The left atrium in heart failure with preserved ejection fraction: What we know and what we do not know

Haykal, R., Kassar, A., Chamoun, N., & AKOUM, N. W. (2025) · Heart Rhythm O2 · doi:10.1016/j.hroo.2025.04.007 · Cited by 14

Cellular Interactions and Immunometabolic Mechanisms in Heart Failure With Preserved Ejection Fraction: From Molecular Mechanisms to Clinical Evidence

Peikert, A., Vacca, A., Norata, G. D., Schiattarella, G. G., & Osto, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012674 · Cited by 16

The role of macrophages in right ventricular remodeling in experimental pulmonary hypertension

Gu, S., Mickael, C. S., Kumar, R., Lee, M. H., Sanders, L., Kassa, B., Harral, J. W., Williams, J. S., Hansen, K. C., Stenmark, K. R., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12105 · Cited by 14

Prognostic implications of six-minute walking distance in patients with heart failure with preserved ejection fraction

Fujimoto, Y., Maeda, D., Kagiyama, N., Sunayama, T., Dotare, T., Jujo, K., Saito, K., Kamiya, K., Saito, H., Ogasahara, Y., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.025 · Cited by 14

Heart failure with preserved ejection fraction

Alsamara, M., & Alharethi, R. A. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.911086 · Cited by 14

Associations of Circulating Vascular Cell Adhesion Molecule‐1 and Intercellular Adhesion Molecule‐1 With Long‐Term Cardiac Function

Mathew, D. T., Peigh, G., Lima, J. A. C., Bielinski, S. J., Larson, N. B., Allison, M., Shah, S. J., & Patel, R. B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032213 · Cited by 14

The Future Diagnosis of Heart Failure with Normal Ejection Fraction: Less Imaging, More Biomarkers?

Franssen, C., & Paulus, W. J. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr106 · Cited by 14

Does inflammation trigger fibrosis in hypertrophic cardiomyopathy: a burning question?

Westermann, D. (2012) · Heart · doi:10.1136/heartjnl-2012-301730 · Cited by 14

CCR2 + monocyte-derived macrophages drive cardiac hypertrophy in early HFpEF

Raman, J., Simmonds, S. J., Caluwé, E., van Leeuwen, R. E. W., Walschap, C., Stroobants, M., Cöl, Ü., Vandervoort, P., Heymans, S. R. B., & Jones, E. A. V. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00022.2025 · Cited by 16

Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction

Graziani, F., Lillo, R., & Crea, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678530 · Cited by 14

Relationship between heart failure and intestinal inflammation in infants with congenital heart disease

Zhang, Q., Chen, X., Zhou, S., Lei, Y., Chen, Q., & Cao, H. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03229-0 · Cited by 13

Leucocyte Count Predicts Cardiovascular Risk in Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas

Bajaj, N. S., Kalra, R., Gupta, K., Aryal, S. R., Rajapreyar, I. N., Lloyd, S. G., McConathy, J., Shah, S. J., & Prabhu, S. D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12724 · Cited by 13

Sweat the small stuff: The human microvasculature and heart disease

Katunaric, B., Cohen, K. E., Beyer, A., Gutterman, D. D., & Freed, J. K. (2020) · Microcirculation · doi:10.1111/micc.12658 · Cited by 13

Vascularisation of pluripotent stem cell–derived myocardium: biomechanical insights for physiological relevance in cardiac tissue engineering

King, O., Sunyovszki, I., & Terracciano, C. M. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02557-8 · Cited by 13

Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis

Kobusiak−Prokopowicz, M., Kaaz, K., Marciniak, D. M., Karolko, B., & Mysiak, A. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000519594 · Cited by 13

Sex Differences in Cardiovascular Physiology and Pathophysiology

Regitz‐Zagrosek, V., Ventura‐Clapier, R., den Ruijter, H. M., Garnier, A., Barcena, M. L., Eikendal, A. L. M., & Hartman, R. J. G. (2019) · Elsevier eBooks · doi:10.1016/c2014-0-02648-2 · Cited by 13

Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction

Zhang, M., Shu, H., Chen, C., He, Z., Zhou, Z., & Wang, D. W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113326 · Cited by 13

Sex differences and related estrogenic effects in heart failure with preserved ejection fraction

Deng, S., Lin, J., Zhao, Z., & Guanwei, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10274-2 · Cited by 13

Epidemiology, Diagnosis, Pathophysiology, and Initial Approach to Heart Failure with Preserved Ejection Fraction

Anderson, T., Hummel, S. L., & Konerman, M. C. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.07.001 · Cited by 14

Notch1 signaling activation alleviates coronary microvascular dysfunction through histone modification of Nrg-1 via the interaction between NICD and GCN5

Qin, X., Shan, Y., Dou, M., Li, F., & Guo, Y. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01777-2 · Cited by 13

Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice

de Haan, J. J., Bosch, L., Borgman, A., Bastemeijer, M., Brans, M. A. D., van de Weg, S. M., de Kleijn, D. P. V., Sluijter, J. P. G., el Azzouzi, H., & de Jager, S. C. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-16957-3 · Cited by 13

Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits

Nachar, W., Merlet, N., Maafi, F., Shi, Y., Mihalache-Avram, T., Mecteau, M., Ferron, M., Rhéaume, É., & Tardif, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220707 · Cited by 13

Myocardial Expression of the Anaphylatoxin Receptor C3aR is Associated with Cardiac Inflammation and Prognosis in Patients with Non-Ischaemic Heart Failure

Mueller, K. A. L., Patzelt, J., Sauter, M., Maier, P., Gekeler, S., Klingel, K., Kandolf, R., Seizer, P., Gawaz, M., Geisler, T., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12298 · Cited by 12

Inflammation associated with left ventricular hypertrophy in bipolar disorder: A cross-sectional study

Tsai, S., Chen, P., Hsiao, C., Sajatovic, M., Huang, Y., & Chung, K. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111465 · Cited by 12

Inhibitors of NLRP3 Inflammasome Formation: A Cardioprotective Role for the Gasotransmitters Carbon Monoxide, Nitric Oxide, and Hydrogen Sulphide in Acute Myocardial Infarction

Payne, F. M., Dabb, A. R., Harrison, J. C., & Sammut, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179247 · Cited by 13

Focusing on microvascular function in heart failure with preserved ejection fraction

Velollari, O., Rommel, K., Kresoja, K., Lurz, P. C., & Gori, T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-024-10479-7 · Cited by 12

Obesity and Heart Failure: Mechanistic Insights and the Regulatory Role of MicroRNAs

Sahu, P., Bestepe, F., Vehbi, S., Ghanem, G. F., Blanton, R. M., & Icli, B. (2025) · Genes · doi:10.3390/genes16060647 · Cited by 12

Breakthrough in heart failure with preserved ejection fraction: are we there yet?

Lim, S. L., & Lam, C. S. P. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.31.1.1 · Cited by 13

Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life

Cohen, A., TERAMOTO, K., Claggett, B. L., Buckley, L. F., Solomon, S. D., Ballantyne, C. M., Selvin, E., & Shah, A. M. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.006 · Cited by 12

Antagonizing the CX3CR1 Receptor Markedly Reduces Development of Cardiac Hypertrophy After Transverse Aortic Constriction in Mice

Nemska, S., Gassmann, M., Bang, M.-L., Frossard, N., & Tavakoli, R. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001130 · Cited by 12

Myocardial Oedema as a Consequence of Viral Infection and Persistence—A Narrative Review with Focus on COVID-19 and Post COVID Sequelae

Panagiotides, N. G., Poledniczek, M., Andreas, M., Hülsmann, M., Kocher, A. A., Kopp, C. W., Piechota-Polańczyk, A., Weidenhammer, A., Pávó, N., & Wadowski, P. P. (2024) · Viruses · doi:10.3390/v16010121 · Cited by 12

Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases

Panico, C., & Condorelli, G. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8624-5 · Cited by 12

Systemic Lupus Erythematosus and Systemic Autoimmune Connective Tissue Disorders behind Recurrent Diastolic Heart Failure

Blasco, L. M., Acha, O., González-Fernández, C. R., Robledo, F. N., & Amunárriz, E. P.-L. (2011) · Clinical and Developmental Immunology · doi:10.1155/2012/831434 · Cited by 12

Diagnostic and Prognostic Value of CMR T 1 -Mapping in Patients With Heart Failure and Preserved Ejection Fraction

Rommel, K., Lücke, C., & Lurz, P. C. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.018 · Cited by 12

Abstract 5881: Influence Of Cardiac Inflammation And Extracellular Matrix Regulation On Diastolic Dysfunction In Patients With Heart Failure With Normal Ejection Fraction

Westermann, D., Kašner, M., Lettau, O., Noutsias, M., Schultheiß, H., & Tschöpe, C. (2008) · Circulation · doi:10.1161/circ.118.suppl_18.s_1021-a · Cited by 1

Extracellular matrix remodeling in early cardiac fibrosis and diastolic dysfunction

Willmer, M., Szardien, S., Kraft, D., Voss, S., Troidl, C., Hoffmann, J., Liebetrau, C., NEF, H. M., Hamm, C. W., & Moellmann, H. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht309.p4197 · Cited by 1

Die intramyokardiale Inflammation als Ursache für Veränderungen der extrazellulären Matrix bei Herzinsuffizienz mit normaler Ejektionsfraktion

Westermann, D. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7911

The Cardiac Fibroblast in heart failure – an inflammatory cell

Thottakara, T., Dhople, V. M., Voss, S., Schoen, J., Völker, U., Blankenberg, S., Westermann, D., Hammer, E., & Lindner, D. (2020) · European Heart Journal · doi:10.1093/ehjci/ehaa946.3731 · Cited by 3

Molecular differences in matrix remodelling in HFNEF and HFREF patients

Lindner, D., Tschöepe, C., & Westermann, D. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht309.p4200